58results about How to "Piece weight small" patented technology

The secnidazole tablet contains secnidazole 50-90 wt%, microcrystalline cellulose, starch, pre-gelatinized starch and/or lactose 0.5-40 wt%, cross-linked sodium carboxymethyl cellulose and/or cross-linked polyvinyl pyrrolidone 0.5-9 wt%, polyvinyl pyrrolidone or hydroxypropylmethyl cellulose 0.1-2.5 wt%, magnesium stearate 0.5-1 wt%, and talcum powder and/or fine silica gel powder 0.5-1 wt%. The preparation process of the secnidazole tablet includes the steps of mixing the said materials, palletizing and tabletting. The secnidazole tablet has high effective component content, easy swallowing, no bitter taste and fast leaching.

The invention provides a Metformin Hydrochloride slow release tablet and process for preparation, wherein the slow release tablet comprises metformin hydrochloride 46.5-70%, hydroxypropylcellulose 13.5-33.0%, micronization ethyl cellulose 10.0-14.0%, filling agent 1.3%-9.4%, and lubricating agent 1.2-1,5%. The preparation process comprises processing the prescribed raw material of metformin hydrochloride, cellulose glycollic ether, and the filling agent through the conventional tablet production process of granulation, drying, granulating, charging micronization ethyl cellulose, mixing homogenously with lubricant and tabletting.

The invention provides a phloroglucinol oral disintegrating tablet, which takes the phloroglucinol as the active ingredient, and disintegrating agents, fillers, lubricants, flavoring agents, binding agents and effervescent agents are added for preparation. The invention further provides a preparation method of the phloroglucinol oral disintegrating tablet. The phloroglucinol oral disintegrating tablet of the invention not only has the rapid disintegration, good taste and no sense of gravel, but can also can be taken under the condition of no water and have the rapid action and more convenient taking, so the invention can improve the compliance of the patients and the efficacy of the drug and other features of the orally disintegrating tablet, at the same time, the invention has light tablet weight, small volume, no powder falling, good brittleness and better dissolution effect than the freeze-dried orally disintegrating tablet. The production cost is low, the dissolution is faster, the invention is more beneficial to the absorption, and the invention can play the effect of pain reliving faster. The invention has the advantage that the invention can carry out the preparation by only adopting the ordinary pressing equipments and the simple technique without the need of special production equipments and conditions.

The invention relates to a pellet preparation, in particular to a spleen-invigorating bolus (pellet) for tonifying qi and invigorating spleen; the spleen-invigorating bolus (pellet) disclosed by the invention is composed of the following components in parts by weight: 66 parts of codonopsis pilosula, 131 parts of fried bighead atractylodes rhizome, 66 parts of astragalus membranaceus baked with honey, 33 parts of liquorice baked with honey, 131 parts of poria cocos, 131 parts of prepared polygala tenuifolia, 66 parts of fried spina date seed, 131 parts of longan aril, 131 parts of Chinese angelica, 33 parts of elecampane, and 33 parts of denucleated Chinese-date; the spleen-invigorating bolus (pellet) contains 10-500 parts by weight of pharmaceutic adjuvants, preferably 20-100 parts by weight. The invention further relates to a preparation method of the spleen-invigorating bolus (pellet); the traditional spleen-invigorating bolus is prepared into the spleen-invigorating bolus (pellet), the bolus diameter of which is 3.5-4 mm, and therefore, the spleen-invigorating bolus (pellet) has the advantages of being steady in quality, obvious in pharmaceutical effect and good in fluidity and dissolution rate and is very applied to clinical use.

The invention discloses a stable perindopril indapamide tablet and a preparation technology. The pharmaceutical composition is composed of the following components: perindopril tert-butylamine, indapamide, lactose, hydroxypropyl cellulose, sodium carboxymethyl starch, silicon dioxide, and magnesium stearate. Powder is directly pressed to prepare the pharmaceutical composition. The properties, dissolution rate, water content, content, crystal form, and dissolving-out behavior in different medium with different pH values of the prepared perindopril indapamide tablet are similar with those of commercial products. Furthermore, the dissolution curve shows that the difference of tablets in a batch and the difference of tablets in different batches is prominently less than that of commercial products. Compared with the commercial products, the stability of the provided tablet is better in production and storage. The clinical effectiveness and safety are guaranteed. Moreover, the preparation technology is simple, and the production cost is reduced.

The invention relates to a preparation method for an omeprazole enteric coated tablet. The components comprise in percents by weight: 10-50% of omeprazole, 1.25-6.25% of superfine silica powder, 30-78% of lactose, 2-3% of copolyvinylpyrrolidone, 5-12% of crospovidone, 1.5-2.0% of sodium octadecyl fumarate and 0.5-1.0% of magnesium stearate. The preparation method comprises: uniformly mixing micronized omeprazole and superfine silica powder, sieving; sieving copolyvinylpyrrolidone, crospovidone, lactose and sodium octadecyl fumarate, uniformly mixing with omeprazole and superfine silica powder, adding into a drying-method granulator, granulating for 3-4 times, screening out integrated particles with a 60 mesh sieve and obtaining dry particles; blending uniformly the dry particles and magnesium stearate by a three-dimensional mixer, adding into a tablet press for pressing tablets; and then coating to obtain the omeprazole enteric coated tablet. The formula is simple; the preparation method helps to solve the industrialized production problem of omeprazole enteric coated tablet high-specification products such as a product with a specification of 40 mg/tablet; and the preparation is controllable in quality, the product is good in uniformity, and impurity content is low.

The invention discloses a preparation method of tenofovir disoproxil fumarate oral tablet, which comprises micronization of raw and auxiliary materials, preparation of pregelatinized starch suspension and fluidized bed granulation and tableting process technical processing, thereby reducing particle size, tablet weight, and difficulty in swallowing, making it easier for patients to accept, and at the same time speeding up its disintegration rate, and improving oral administration of tenofovir disoproxil Bioavailability of esters.

The invention discloses a mycophenolate mofetil dispersible tablet. The tablet consists of mycophenolate mofetil, calcium sulfate, glycerin monostearate, a disintegrating agent and an adhesive. Compared with the prior art, the mycophenolate mofetil dispersible tablet prepared by the invention is small in tablet weight and rapid in dissolution and disintegration and does not need lots of disintegrating agents, the disintegrated granules can smoothly pass through a No.2 sieve, and the mycophenolate mofetil dispersible tablet is suitable for industrial production.

The invention discloses a brand-new oral solid pharmaceutical composition. The pharmaceutical composition is an oral preparation prepared from hydrochlorothiazide, l-amlodipine, olmesartan medoxomil and pharmaceutically acceptable auxiliary materials, and the oral preparation comprises but is not limited to tablets or capsules. The composition comprises the following raw materials in parts by weight: 5-25 parts of hydrochlorothiazide, 2.5-5 parts of l-amlodipine, 20-40 parts of olmesartan medoxomil, 40-120 parts of microcrystalline cellulose, 30-90 parts of pregelatinized starch, 15-40 parts of low-substituted hydroxypropyl cellulose, 10-45 parts of crosslinked polyvinylpyrrolidone, 3-8 parts of silica and 1-2 parts of magnesium stearate. The pharmaceutical composition disclosed by the invention has the advantages of scientific and reasonable prescription, low auxiliary material content and high bioavailability, and is a drug of first choice for treating hypertension.

The invention belongs to the field of medicinal preparations, and discloses an indissolvable drug oral sustained-release dry emulsion tablet and a preparation method thereof. The preparation method for the oral sustained-release dry emulsion tablet comprises the steps that after an oil phase, a surface active agent and cosurfactant are evenly mixed, an indissolvable drug is added till the drug is dissolved completely, and accordingly a medicine-carried self-emulsifying system is prepared; after the medicine-carried self-emulsifying system and an aqueous solution of a hydrophilic gel framework material are evenly mixed, spray drying is conducted, and sustained-release dry emulsion powder is obtained; after the sustained-release dry emulsion powder and a conventional tablet auxiliary material needed for preparation are mixed, wet granulation is carried out; at last, tabletting is performed. The sustained-release dry emulsion tablet can improve the dissolution and dissolving-out performance of the indissolvable drug, the bioavailability of the indissolvable drug is improved, a stable blood concentration is formed, and the compliance of patients is improved. The sustained-release dry emulsion tablet is not complex in composition of prescription, and the preparation technology is suitable for industrial production.

The invention relates to a pellet preparation, and in particular relates to a wind-dispelling and hair-restoring alopecia areata pellet. The pellet comprises the following components in parts by weight: 148 parts of rehmannia, 148 parts of prepared rehmannia, 148 parts of prepared polygonum multiflorum, 98 parts of Chinese angelica, 98 parts of salvia miltiorrhiza, 98 parts of white peony root, 98 parts of schisandra chinensis, 50 parts of notopterygium root, 50 parts of pawpaw, and 10-1,000 parts of medical auxiliaries. The invention also relates to a preparation method of the alopecia areata pill (pellet). By adopting the method, alopecia areata pellet with diameter of 3.5-4mm is prepared from the traditional alopecia areata pill, so that the alopecia areata pellet is stable in quality and remarkable in drug effect, has extremely good fluidity and dissolution, and is suitable for clinical application.

The invention relates to a novel preparation process for a solid oral preparation which comprises the active components consisting of an oral active renin inhibitor (aliskiren) in an appropriate carrier medium or a medicinal salt thereof and a calcium channel blocker (CCB) amlodipine/levamlodipine or a medicinal salt thereof. Particularly, the invention provides a galenical preparation which comprises a composition of aliskiren hemifumarate and amlodipine or levamlodipine and a novel preparation process. The invention also relates to novel preparation methods for the above-mentioned preparations and application of the preparations as medicines. According to the invention, the method of dry granulation is employed, the problem that the method of wet granulation easily causes increase of relevant substances is overcome, and drug stability is improved; through optimization of the process, the usage amount of excipients is reduced, the purpose of reducing the weight of a tablet is achieved, cost is saved, and the preparations can be easily taken; through particle coating, unwanted reaction of two drugs after mixing is prevented.

The invention discloses a metronidazole effervescent tablet for vagina and a preparation technology of the metronidazole effervescent tablet. The tablet is prepared from a metronidazole tablet core and an alkaline coating layer, wherein the metronidazole tablet core contains an acid component; and the metronidazole tablet core is wrapped with the alkaline coating layer. Compared with the prior art, an acid effervescing agent and an alkaline effervescing agent are effectively separated; the problem of the stability of the metronidazole effervescent tablet in preparation and storage processes is successfully solved; meanwhile, the amount of auxiliary materials is greatly reduced; the tablet weight is reduced; and medication of patients is facilitated.

The invention provides trelagliptin succinate tablets and a preparation method thereof. The trelagliptin succinate tablets contain the following components in parts by weight: 64.0%-78.2% of trelagliptin succinate, 3.7%-5.0% of cross-linking sodium cellulose glycolate, 2.2%-5.0% of hydroxypropyl cellulose, 6.8%-25.1% of mannitol, 6.8%-15.2% of microcrystalline cellulose and 0.1%-5% of sodium stearoyl fumarate. The invention aims at providing the trelagliptin succinate tablets with even quality, high disintegration speed, good digestion degree, small tablet weight, simple production process, easy operation and suitability for industrial production.

The invention discloses a metformin hydrochloride controlled-release tablet and a preparation method thereof. The metformin hydrochloride controlled-release tablet comprises a tablet core, a coating aqueous dispersion forms a controlled-release coating film outside the tablet core, and the tablet core is prepared from, by weight, 80-120 parts of metformin hydrochloride, 10-14 parts of a tablet core controlled-release material, 2-4 parts of filler and 0.2-1.2 parts of an adhesive, and the aqueous dispersion is prepared from the following raw materials in parts by weight: 2 to 6 parts of coatingslow-release material, 1.2 to 1.6 parts of plasticizer, 1.2 to 1.6 parts of pore-foaming agent, 0.4 to 0.8 part of anti-sticking agent and 0.1 to 0.5 part of emulsifying agent. The controlled-releasetablet provided by the invention is coated by adopting the aqueous dispersion, so that the pollution of an organic solvent to the environment is avoided, and the potential safety hazard is reduced. According to the invention, a double controlled release technology of tablet core slow release and membrane controlled coating is adopted, the release degree in the second hour is 10%-35%, the releasedegree in the sixth hour is 40%-70% and the release degree in the twelfth hour is more than 80% in an in-vitro release degree test, constant-speed release is realized, swallowing is easy, and the compliance of a patient is improved.

The invention discloses a clopidogrel sulfate tablet and a preparation process thereof. The tablet contains compound of clopidogrel sulfate and polyvinylpolypyrrolidone, wherein the compound is prepared by the steps of dissolving clopidogrel sulfate in an alcohol solvent, adding polyvinylpolypyrrolidone, uniformly mixing and drying by spray. The clopidogrel sulfate and polyvinylpolypyrrolidone compound prepared by the process is capable of avoiding adhesion in the producing process and successfully solving the stability problem in clopidogrel sulfate preparing and storing processes, is simple in process, and is easy for industrial large-scale production.

The invention relates to pharmaceutical compositions, in particular to an olaparib release related pharmaceutical composition. The invention discloses an olaparib composition containing impurities with relatively low levels and having relatively high release level, and a method for maintaining the stability of such pharmaceutical compositions.

The invention belongs to the field of pharmaceutical preparations, and discloses a metformin hydrochloride dual controlled release composition, which is prepared from a controlled release coating film coated outside a tablet core of metformin hydrochloride containing a controlled release material, the metformin hydrochloride tablet core containing the sustained-release material is composed of metformin hydrochloride, the sustained-release material, a filling agent and an adhesive, the coating layer is composed of a coating sustained-release material, a plasticizer and a pore-foaming agent, the coating sustained-release material is cellulose acetate, the tablet core sustained-release material is a mixture of octadecanol and polyoxyethylene, and the coating sustained-release material is cellulose acetate. According to the technical scheme, compared with a traditional film-coated controlled release tablet, the film-controlled metformin hydrochloride dual controlled release composition has the advantages that the time for keeping the stable release degree is longer, the storage stability is better, the process is simple, expensive production equipment is not needed, the cost is low, and industrialization is easy.

The invention provides metformin hydrochloride controlled-release tablets and a preparation method thereof. The metformin hydrochloride controlled-release tablets contain a main drug namely metforminhydrochloride, an auxiliary material namely a filler, an auxiliary material namely a sustained-release material, and auxiliary materials namely an adhesive and a sustained-release coating, and is characterized in that the metformin hydrochloride, the filler and the sustained-release material are pressed into a tablet core; the sustained-release material in the tablet core and the sustained-releasecoating film outside the tablet core form a double controlled-release system of a controlled-release drug, the sustained-release material is a mixture of octadecanol and polyoxyethylene, the ratio ofthe octadecanol to the polyoxyethylene in parts by weight is 3: 1, and the molecular weight of the polyoxyethylene is 400,000-900,000. The metformin hydrochloride controlled release tablets providedby the invention have a release rate of 7%-10% per hour, can be released at a constant speed for about 10 hours, is clinically verified to have a low adverse reaction rate after being taken by a patient, and obviously improves the tolerance of the patient.

The invention relates to an improved Zhenyuan tablet and a preparation method thereof in the technical field of pharmaceutical preparations. The improved Zhenyuan tablet includes a tablet core and a coating, wherein the tablet core includes ginseng fruit saponins and a sustained-release material, and the coating includes a sustained-release coating material. By adding the sustained-release material in the tablet core and adopting the coating containing the sustained-release coating material, the slow release time of the Zhenyuan tablet is prolonged, and the bioavailability of ginseng fruit saponins in the Zhenyuan tablet is improved. The Zhenyuan tablet has a good slow-release effect. Each 1000 Zhenyuan tablets preferably include the following ingredients: 25 g of ginseng fruit saponins, 28.5 g of starch, 60 g of lactose monohydrate, 1.52 g of povidone, 2 g of silica, 0.5 g of magnesium stearate and 2.01 g of gastric soluble opadry. The povidone is used as both a sustained-release material and a binder to reduce the tablet weight.

The invention relates to the technical field of pharmaceutical preparations, in particular to a metformin hydrochloride tablet and a preparation method thereof. The components of the metformin hydrochloride tablet comprise metformin hydrochloride, a binder, a framework film material and a lubricant, wherein the framework film material is selected from at least one of sodium stearate, magnesium stearate, stearic acid and the like. The preparation method of the tablet is a one-step granulation method. The in-vitro dissolution condition of the provided metformin hydrochloride tablet is highly similar to that of an original triturate, the tablet has excellent inter-batch stability, and the in-batch and inter-batch dissolution uniformity and inter-batch reproducibility of the tablet are superior to those of the original triturate.